S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
Log in

OTCMKTS:HSDT - Helius Medical Technologies Stock Price, Forecast & News

$0.91
-0.02 (-2.15 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$0.87
Now: $0.91
$0.96
50-Day Range
$0.84
MA: $1.01
$1.46
52-Week Range
$0.28
Now: $0.91
$7.47
Volume38,469 shs
Average Volume275,920 shs
Market Capitalization$27.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain's ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:HSDT
CUSIPN/A
Phone215-944-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$27.57 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive HSDT News and Ratings via Email

Sign-up to receive the latest news and ratings for HSDT and its competitors with MarketBeat's FREE daily newsletter.


Helius Medical Technologies (OTCMKTS:HSDT) Frequently Asked Questions

What is Helius Medical Technologies' stock symbol?

Helius Medical Technologies trades on the OTCMKTS under the ticker symbol "HSDT."

How were Helius Medical Technologies' earnings last quarter?

Helius Medical Technologies Inc (OTCMKTS:HSDT) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.25) by $0.03. The company earned $0.52 million during the quarter, compared to analyst estimates of $0.40 million. View Helius Medical Technologies' Earnings History.

When is Helius Medical Technologies' next earnings date?

Helius Medical Technologies is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Helius Medical Technologies.

What price target have analysts set for HSDT?

2 Wall Street analysts have issued 12 month price targets for Helius Medical Technologies' shares. Their forecasts range from $10.00 to $10.00. On average, they expect Helius Medical Technologies' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 999.5% from the stock's current price. View Analyst Price Targets for Helius Medical Technologies.

What is the consensus analysts' recommendation for Helius Medical Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Helius Medical Technologies in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Helius Medical Technologies.

What are Wall Street analysts saying about Helius Medical Technologies stock?

Here are some recent quotes from research analysts about Helius Medical Technologies stock:
  • 1. According to Zacks Investment Research, "Helius Medical Technologies Inc. is a specialty medical device company. It is focused on the development and regulatory approval of its non-invasive neurostimulation device called PoNS. The Company is nearing clinical trials for balance disorders in TBI patients and for the treatment of MS. Helius Medical Technologies, Inc. is based in Newtown, Pennsylvania. " (1/15/2020)
  • 2. BTIG Research analysts commented, "of Medical reported ~$500K in licensing revenue in Q4 and set 2019 sales guidance of $1.6-$2.0M. This outlook assumes that only the two Canadian centers currently treating commercial patients will contribute to 2019 revenue. We see this as a prudent approach and think this leaves some potential for upside as additional Canadian centers are slated to be added throughout the year. Importantly, HSDT has filed a response to the FDA’s request for more information on the PoNS device. We do not have any insight into the US timeline or the potential for additional questions from the agency but continue to believe approval is more likely than not based on clinical benefit and strong safety profile. In our view, the near- term stock price is likely to be driven by updates from the FDA rather than Canadian commercial launch or revenue reports." (3/18/2019)

Has Helius Medical Technologies been receiving favorable news coverage?

Press coverage about HSDT stock has trended very negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Helius Medical Technologies earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Helius Medical Technologies.

Who are some of Helius Medical Technologies' key competitors?

What other stocks do shareholders of Helius Medical Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Helius Medical Technologies investors own include Mazor Robotics (MZOR), Energy Transfer LP Unit (ET), G&K Services (GK), Martin Midstream Partners (MMLP), Opko Health (OPK), Franco Nevada (FNV), AT&T (T), Tapestry (TPR), Actinium Pharmaceuticals (ATNM) and AcelRx Pharmaceuticals (ACRX).

Who are Helius Medical Technologies' key executives?

Helius Medical Technologies' management team includes the folowing people:
  • Philippe Deschamps, President, Chief Executive Officer, Director
  • Joyce N. LaViscount, Chief Financial Officer, Chief Operating Officer
  • Brian Bapty, Vice President, Strategy and Business Development
  • Jonathan Sackier, Chief Medical Officer
  • Dane Andreeff, Director
  • Huaizheng Peng, Director
  • Mitch Eugene Tyler, Director
  • Thomas E. Griffin, Independent Director
  • Edward M. Straw, Independent Director

Who are Helius Medical Technologies' major shareholders?

Helius Medical Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.55%) and Virtu Financial LLC (0.28%). Company insiders that own Helius Medical Technologies stock include Dane Andreeff and Thomas E Griffin. View Institutional Ownership Trends for Helius Medical Technologies.

Which major investors are buying Helius Medical Technologies stock?

HSDT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Virtu Financial LLC. Company insiders that have bought Helius Medical Technologies stock in the last two years include Dane Andreeff and Thomas E Griffin. View Insider Buying and Selling for Helius Medical Technologies.

How do I buy shares of Helius Medical Technologies?

Shares of HSDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Helius Medical Technologies' stock price today?

One share of HSDT stock can currently be purchased for approximately $0.91.

How big of a company is Helius Medical Technologies?

Helius Medical Technologies has a market capitalization of $27.57 million. View Additional Information About Helius Medical Technologies.

What is Helius Medical Technologies' official website?

The official website for Helius Medical Technologies is http://www.heliusmedical.com/.

How can I contact Helius Medical Technologies?

Helius Medical Technologies' mailing address is 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940. The company can be reached via phone at 215-944-6100 or via email at [email protected]


MarketBeat Community Rating for Helius Medical Technologies (OTCMKTS HSDT)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  264
MarketBeat's community ratings are surveys of what our community members think about Helius Medical Technologies and other stocks. Vote "Outperform" if you believe HSDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSDT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel